

2024 Independent Medical Education Request for Proposals

Issue Date: July 16, 2024

The *Independent Medical Education team at Genentech, a member of the Roche Group*, invites accredited educational providers to submit applications for independent, certified medical education grants subject to the terms described below. This Request for Proposals (RFP) provides public notice of the availability of funds in a general topic area for activities for which recognized scientific or educational needs exist and funding is available.

Purpose: As part of Genentech’s scientific mission, Genentech supports grants for independent medical education that aim to improve patient care by focusing on the improved application of knowledge, competence, and performance among healthcare professionals. This mission is achieved by supporting quality independent education that addresses evidence-based, bona fide educational gaps in accordance with the ACCME, AMA, PhRMA Code, OIG and FDA guidance.

Notification: Genentech RFPs are made available through our online Genentech Funding Request System (gFRS) site (<http://funding.gene.com>) along with the websites for the Alliance for Continuing Education in the Health Professions (ACEhp). In addition, an email is distributed to all registered gFRS users who have previously applied for support of an independent education activity. The email distribution list may not always be up to date. Please periodically check our online Genentech Funding Request System (gFRS) site (<http://funding.gene.com>) to stay informed on current funding priorities. *There have been no predetermined approvals, nor any identified preferred educational providers. All submissions will be reviewed equally and thoroughly.*

Terms and Conditions

1. All grant applications received in response to this RFP will be reviewed in accordance with all Genentech policies and policy guidelines. (Please refer to the publicly available criteria on <http://funding.gene.com>)
2. This RFP does not commit Genentech to award a grant or pay any costs incurred in the preparation of a response to this request.
3. Genentech reserves the right to approve or deny any or all applications received as a result of this request or to cancel, in part or in its entirety, this RFP.
4. For compliance reasons, and in fairness to all providers, all communications about this RFP must come exclusively to Genentech’s department of Medical Education and Research Grants. Failure to comply will automatically disqualify providers.
5. Failure to follow the instructions within this RFP may result in a denial.

Instructions

Eligibility Criteria	<ul style="list-style-type: none"> ● U.S. based education provider ● Registered account in gFRS ● Accredited to provide CME/CE and in good standing (e.g. ACCME, ANCC, ACPE, etc.)
Geographical Scope	<ul style="list-style-type: none"> ● Educational initiatives must be U.S.-based only

Submission Directions	Application Process	Deadlines
Step 1	Providers who meet the eligibility criteria and are interested in submitting a response to this RFP will have 5 weeks to complete a full grant proposal through funding.gene.com . When submitting the application, please be sure to: <ul style="list-style-type: none"> • Select the Therapeutic Area (Neuroscience), and Disease State (Multiple Sclerosis) • Include “RFP Jul 2024 [Insert Program Title]” in the program title of the grant 	August 20, 2024
Step 2	Grant decisions will be made by Genentech by August 26, 2023 and decision notifications will be issued to the accredited educational provider through gFRS.	August 26, 2024
Step 3	If your grant is approved, one activity within the program must launch before October 31, 2024.	October 31, 2024

Additional Considerations

Provider(s) who are awarded grants are encouraged but not required to:

1. Demonstrate key findings via outcomes analysis and report the extent to which the education met the stated objectives and other key findings.
2. Describe how learners demonstrated competence, performance, or improved patient outcomes as a result of the educational activity.
3. Summarize (through written analysis) the provider’s understanding and interpretation of the outcomes data and identify any persistent educational gaps, unanticipated barriers and/or activity/outcomes limitations.

Currently Available RFP Focus Area:

Focus	Opportunity
<p>Therapeutic Area: Neuroscience</p> <p>Disease Areas: Multiple Sclerosis</p> <p>Learning Audiences:</p> <ol style="list-style-type: none"> 1. US-based General Neurologists who treat multiple sclerosis patients 2. Multiple Sclerosis patients <p>Support Available: Up to \$500,000</p>	<p>Disease and disability progression are important factors to understand for both healthcare providers managing patients with multiple sclerosis (MS) as well as for patients experiencing the disease themselves.</p> <p>The scientific community's understanding of multiple sclerosis has grown over the years and there is a wealth of data being reported regularly to help neurologists and their patients personalize disease management in MS. Recent data has provided further information on the measurement of MS beyond annualized relapse rate (ARR).¹</p> <p>It is important to be mindful of the clinical relevance of newer concepts of silent progression in MS, like progression independent of relapse activity (PIRA), relapse associated worsening (RAW), and associated measures.²⁻⁵</p> <p>We are requesting proposals that can help to address the educational gap in evaluating and measuring outcomes in multiple sclerosis and aid in neurologists ability to improve the recognition of progression when it occurs and how to best discuss with patients.</p> <p>References:</p> <ol style="list-style-type: none"> 1. Kister I, Chamot E, Salter AR, Cutter GR, Bacon TE, Herbert J. Disability in multiple sclerosis: a reference for patients and clinicians. <i>Neurology</i>. Mar 12 2013;80(11):1018-1024. 2. van Munster CE, Uitdehaag BM. Outcome Measures in Clinical Trials for Multiple Sclerosis. <i>CNS Drugs</i>. 2017 Mar;31(3):217-236. doi: 10.1007/s40263-017-0412-5. PMID: 28185158; PMCID: PMC5336539. 3. Tur C, Carbonell-Mirabent P, Cobo-Calvo A, et al. Association of Early Progression Independent of Relapse Activity With Long-term Disability After a First Demyelinating Event in Multiple Sclerosis. <i>JAMA Neurol</i>. 2023;80(2):151-160 4. Kuhlmann T, Moccia M, Coetzee T, et al. Multiple sclerosis progression: time for a new mechanism-driven framework. <i>Lancet Neurol</i>. 2023 Jan;22(1):78-88. 5. Krieger SC, et al. The topographical model of multiple sclerosis. <i>Neurol Neuroimmunol Neuroinflamm</i> 2016;3(5):e279